HPR134 Impact of Loss of Exclusivity on the Expenditure of Medicines: An Analysis on Molecules for Which a Generic or Biosimilar Was Introduced in the Netherlands After 2012
Abstract
Authors
M. van Wijk DNM van der Hoeff SEP Joosten G. van den Boom P Pasman